Surgical oncologist Dr. Diane M. Simeone discusses how the new clinical trial platform increases treatment options for people with pancreatic cancer.
PHOTO: JONATHAN KOZOWYK
A new clinical trial platform鈥攄esigned to test multiple experimental treatments for pancreatic cancer therapies at the same time鈥攈as the potential to reduce the time it takes for people with cancer to enroll in a trial and speed up the approval of new treatments. Launched by the Pancreatic Cancer Action Network (PanCAN), the platform, called Precision Promise鈩, has 15 sites across the United States, including 嘿嘿视频 Health鈥檚 Perlmutter Cancer Center. Diane M. Simeone, MD, the Laura and Isaac Perlmutter Professor of Surgery in the and director of Perlmutter Cancer Center鈥檚 Pancreatic Cancer Center, is the national principal investigator for Precision Promise鈩 at Perlmutter Cancer Center.
鈥淧ancreatic cancer is a difficult enough diagnosis to navigate in and of itself,鈥 Dr. Simeone tells SurvivorNet. 鈥淪o to have a national program like this with centers around the country that have specific expertise in pancreatic cancer, to make it easier for patients to know what options they have and give them more promising new therapies in a way that hasn鈥檛 happened before, it鈥檚 very exciting.鈥
Read more from .
